Familial Primary Pulmonary Hypertension Market

DelveInsight's "Familial Primary Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Familial Primary Pulmonary Hypertension, historical and forecasted epidemiology as well as the Familial Primary Pulmonary Hypertension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Familial Primary Pulmonary Hypertension market report provides current treatment practices, emerging drugs, Familial Primary Pulmonary Hypertension market share of the individual therapies, current and forecasted Familial Primary Pulmonary Hypertension market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Familial Primary Pulmonary Hypertension treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Familial Primary Pulmonary Hypertension market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2019-2032

Familial Primary Pulmonary Hypertension Disease Understanding and Treatment Algorithm

Familial Primary Pulmonary Hypertension (FPAH), also known as Heritable pulmonary arterial hypertension (HPAH), is a type of pulmonary arterial hypertension (PAH) caused by mutations in PAH-causing genes or in a familial setting. Patients with idiopathic pulmonary arterial hypertension (IPAH) who have one or more blood relatives with IPAH are said to have familial PAH, according to the Pulmonary Hypertension Association (FPAH). There is a restriction of blood flow in the small arteries in the lungs in idiopathic pulmonary arterial hypertension (IPAH), formerly known as primary pulmonary hypertension (PPH). 

 

Dyspnea, tiredness, syncope, chest discomfort, palpitations, and pedal edema are among the initial signs. A loud and palpable second heart sound, right ventricular heave, pulmonary ejection click, and murmurs of pulmonary and tricuspid regurgitation are all precordial symptoms.

 

It might be difficult to determine that PAH has a familial basis since the illness can skip generations, which occurs when a patient's parents or grandparents do not have PAH. Patients with sporadic PAH or PAH in a familial context should be examined for BMPR2 gene mutations as soon as possible. 

 

PAH is characterized by pulmonary vascular thickening, which results in reduced blood flow and high blood pressure inside the pulmonary arteries. As a result, the heart has to work harder to pump blood through the pulmonary arteries. The US Food and Drug Administration (FDA) has authorized many drugs for the treatment of PAH. These drugs are broadly classified as Prostaglandins, Endothelin Receptor Antagonists,   Phosphodiesterase Type 5 Inhibitors, other mechanisms and supportive therapies

 

Familial Primary Pulmonary Hypertension Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Familial Primary Pulmonary Hypertension.

 

Familial Primary Pulmonary Hypertension Treatment

It covers the details of conventional and current medical therapies available in the Familial Primary Pulmonary Hypertension market for the treatment of the condition. It also provides Familial Primary Pulmonary Hypertension treatment algorithms and guidelines in the United States, Europe, and Japan.

Familial Primary Pulmonary Hypertension Epidemiology 

The Familial Primary Pulmonary Hypertension epidemiology section provides insights about the historical and current Familial Primary Pulmonary Hypertension patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Familial Primary Pulmonary Hypertension market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Familial Primary Pulmonary Hypertension epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

  • Familial Primary Pulmonary Hypertension (FPAH) represents less than 4 percent of Primary Pulmonary Hypertension.
  • Estimated prevalence of FPAH is < 1/million people.
  • FPAH usually develops in adults, and rarely in children and women are twice more likely to be affected

 

Country Wise- Familial Primary Pulmonary Hypertension Epidemiology

The epidemiology segment also provides the Familial Primary Pulmonary Hypertension epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Familial Primary Pulmonary Hypertension Drug Chapters

The drug chapter segment of the Familial Primary Pulmonary Hypertension report encloses the detailed analysis of Familial Primary Pulmonary Hypertension marketed drugs and late-stage (Phase-III and Phase-II) Familial Primary Pulmonary Hypertension pipeline drugs. It also helps to understand the Familial Primary Pulmonary Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Familial Primary Pulmonary Hypertension Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Familial Primary Pulmonary Hypertension treatment.

 

Key Familial Primary Pulmonary Hypertension Companies

  • Liquidia Technologies
  • Acceleron Pharma
  • Altavant Sciences
  • United Therapeutics
  • Actelion

 

Familial Primary Pulmonary Hypertension Pipeline Therapies

  • Treprostinil
  • Non-Treprostinil PAH Medications
  • Epoprostenol
  • Sotatercept
  • Bosentan
  • UT-15

Familial Primary Pulmonary Hypertension Market Outlook

The Familial Primary Pulmonary Hypertension market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Familial Primary Pulmonary Hypertension market trends by analyzing the impact of current Familial Primary Pulmonary Hypertension therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Familial Primary Pulmonary Hypertension market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Familial Primary Pulmonary Hypertension market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Familial Primary Pulmonary Hypertension market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Familial Primary Pulmonary Hypertension market in 7MM.

 

The United States: Familial Primary Pulmonary Hypertension Market Outlook

This section provides the total Familial Primary Pulmonary Hypertension market size and market size by therapies in the United States.

 

EU-5 Countries: Familial Primary Pulmonary Hypertension Market Outlook

The total Familial Primary Pulmonary Hypertension market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

 

Japan: Familial Primary Pulmonary Hypertension Market Outlook

The total Familial Primary Pulmonary Hypertension market size and market size by therapies in Japan is also mentioned.

Familial Primary Pulmonary Hypertension Drugs Uptake

This section focuses on the rate of uptake of the potential Familial Primary Pulmonary Hypertension drugs recently launched in the Familial Primary Pulmonary Hypertension market or expected to get launched in the market during the study period 2019-2032. The analysis covers Familial Primary Pulmonary Hypertension market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Familial Primary Pulmonary Hypertension Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Familial Primary Pulmonary Hypertension market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Familial Primary Pulmonary Hypertension Pipeline Development Activities

The Familial Primary Pulmonary Hypertension report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Familial Primary Pulmonary Hypertension key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The Familial Primary Pulmonary Hypertension report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Familial Primary Pulmonary Hypertension emerging therapies.

Reimbursement Scenario in Familial Primary Pulmonary Hypertension

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Familial Primary Pulmonary Hypertension market trends, we take KOLs and SMEs ' opinion working in the Familial Primary Pulmonary Hypertension domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Familial Primary Pulmonary Hypertension market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Familial Primary Pulmonary Hypertension Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Familial Primary Pulmonary Hypertension, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Familial Primary Pulmonary Hypertension epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Familial Primary Pulmonary Hypertension is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Familial Primary Pulmonary Hypertension market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Familial Primary Pulmonary Hypertension market

Report Highlights

  • In the coming years, the Familial Primary Pulmonary Hypertension market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Familial Primary Pulmonary Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Familial Primary Pulmonary Hypertension. The launch of emerging therapies will significantly impact the Familial Primary Pulmonary Hypertension market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Familial Primary Pulmonary Hypertension
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Familial Primary Pulmonary Hypertension Report Insights

  • Familial Primary Pulmonary Hypertension Patient Population
  • Therapeutic Approaches
  • Familial Primary Pulmonary Hypertension Pipeline Analysis
  • Familial Primary Pulmonary Hypertension Market Size
  • Familial Primary Pulmonary Hypertension Market Trends
  • Familial Primary Pulmonary Hypertension Market Opportunities
  • Impact of upcoming Familial Primary Pulmonary Hypertension Therapies

Familial Primary Pulmonary Hypertension Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Familial Primary Pulmonary Hypertension Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Familial Primary Pulmonary Hypertension Market
  • Drugs Uptake

Familial Primary Pulmonary Hypertension Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Familial Primary Pulmonary Hypertension Pipeline Product Profiles
  • Familial Primary Pulmonary Hypertension Market Attractiveness
  • Familial Primary Pulmonary Hypertension Market Drivers
  • Familial Primary Pulmonary Hypertension Market Barriers

Key Questions

Familial Primary Pulmonary Hypertension Market Insights:

  • What was the Familial Primary Pulmonary Hypertension drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Familial Primary Pulmonary Hypertension total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Familial Primary Pulmonary Hypertension market size during the forecast period (2019-2032)?
  • At what CAGR, the Familial Primary Pulmonary Hypertension market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Familial Primary Pulmonary Hypertension market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Familial Primary Pulmonary Hypertension market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of the Familial Primary Pulmonary Hypertension?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Familial Primary Pulmonary Hypertension patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Familial Primary Pulmonary Hypertension in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Familial Primary Pulmonary Hypertension?
  • Out of all 7MM countries, which country would have the highest prevalent population of Familial Primary Pulmonary Hypertension during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Familial Primary Pulmonary Hypertension treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of Familial Primary Pulmonary Hypertension in the USA, Europe, and Japan?
  • What are the Familial Primary Pulmonary Hypertension marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Familial Primary Pulmonary Hypertension?
  • How many therapies are in-development by each company for Familial Primary Pulmonary Hypertension treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Familial Primary Pulmonary Hypertension treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Familial Primary Pulmonary Hypertension therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Familial Primary Pulmonary Hypertension and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Familial Primary Pulmonary Hypertension?
  • What are the global historical and forecasted market of Familial Primary Pulmonary Hypertension?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Familial Primary Pulmonary Hypertension market
  • To understand the future market competition in the Familial Primary Pulmonary Hypertension market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Familial Primary Pulmonary Hypertension in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Familial Primary Pulmonary Hypertension market
  • To understand the future market competition in the Familial Primary Pulmonary Hypertension market

1. Key Insights

2. Executive Summary of Familial Primary Pulmonary Hypertension

3. Competitive Intelligence Analysis for Familial Primary Pulmonary Hypertension

4. Familial Primary Pulmonary Hypertension: Market Overview at a Glance

4.1. Familial Primary Pulmonary Hypertension Total Market Share (%) Distribution in 2019

4.2. Familial Primary Pulmonary Hypertension Total Market Share (%) Distribution in 2032

5. Familial Primary Pulmonary Hypertension: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Familial Primary Pulmonary Hypertension Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Familial Primary Pulmonary Hypertension Treatment and Management

8.2. Familial Primary Pulmonary Hypertension Treatment Algorithm

9. Familial Primary Pulmonary Hypertension Unmet Needs

10. Key Endpoints of Familial Primary Pulmonary Hypertension Treatment

11. Familial Primary Pulmonary Hypertension Marketed Products

11.1. List of Familial Primary Pulmonary Hypertension Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Familial Primary Pulmonary Hypertension Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Familial Primary Pulmonary Hypertension: Seven Major Market Analysis

13.1. Key Findings

13.2. Familial Primary Pulmonary Hypertension Market Size in 7MM

13.3. Familial Primary Pulmonary Hypertension Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Familial Primary Pulmonary Hypertension Market Outlook

15.1. United States: Familial Primary Pulmonary Hypertension Market Size

15.1.1. Familial Primary Pulmonary Hypertension Total Market Size in the United States

15.1.2. Familial Primary Pulmonary Hypertension Market Size by Therapies in the United States

15.2. EU-5 countries: Familial Primary Pulmonary Hypertension Market Size and Outlook

15.3. Germany Familial Primary Pulmonary Hypertension Market Size

15.3.1. Familial Primary Pulmonary Hypertension Total Market Size in Germany

15.3.2. Familial Primary Pulmonary Hypertension Market Size by Therapies in Germany

15.4. France Familial Primary Pulmonary Hypertension Market Size

15.4.1. Familial Primary Pulmonary Hypertension Total Market Size in France

15.4.2. Familial Primary Pulmonary Hypertension Market Size by Therapies in France

15.5. Italy Familial Primary Pulmonary Hypertension Market Size

15.5.1. Familial Primary Pulmonary Hypertension Total Market Size in Italy

15.5.2. Familial Primary Pulmonary Hypertension Market Size by Therapies in Italy

15.6. Spain Familial Primary Pulmonary Hypertension Market Size

15.6.1. Familial Primary Pulmonary Hypertension Total Market Size in Spain

15.6.2. Familial Primary Pulmonary Hypertension Market Size by Therapies in Spain

15.7. United Kingdom Familial Primary Pulmonary Hypertension Market Size

15.7.1. Familial Primary Pulmonary Hypertension Total Market Size in the United Kingdom

15.7.2. Familial Primary Pulmonary Hypertension Market Size by Therapies in the United Kingdom

15.8. Japan Familial Primary Pulmonary Hypertension Market Outlook

15.8.1. Japan Familial Primary Pulmonary Hypertension Market Size

15.8.2. Familial Primary Pulmonary Hypertension Total Market Size in Japan

15.8.3. Familial Primary Pulmonary Hypertension Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Familial Primary Pulmonary Hypertension

17. KOL Views

18. Familial Primary Pulmonary Hypertension Market Drivers

19. Familial Primary Pulmonary Hypertension Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Table

Table 1: 7MM Familial Primary Pulmonary Hypertension Epidemiology (2019-2032)

Table 2: 7MM Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases (2019-2032)

Table 3: Familial Primary Pulmonary Hypertension Epidemiology in the United States (2019-2032)

Table 4: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Familial Primary Pulmonary Hypertension Epidemiology in Germany (2019-2032)

Table 6: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Familial Primary Pulmonary Hypertension Epidemiology in France (2019-2032)

Table 8: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Familial Primary Pulmonary Hypertension Epidemiology in Italy (2019-2032)

Table 10: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Familial Primary Pulmonary Hypertension Epidemiology in Spain (2019-2032)

Table 12: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Familial Primary Pulmonary Hypertension Epidemiology in the UK (2019-2032)

Table 14: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: Familial Primary Pulmonary Hypertension Epidemiology in Japan (2019-2032)

Table 16: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Market Size in USD, Million (2019-2032)

Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Familial Primary Pulmonary Hypertension Epidemiology (2019-2032)

Figure 2: 7MM Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases (2019-2032)

Figure 3: Familial Primary Pulmonary Hypertension Epidemiology in the United States (2019-2032)

Figure 4: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5: Familial Primary Pulmonary Hypertension Epidemiology in Germany (2019-2032)

Figure 6: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7: Familial Primary Pulmonary Hypertension Epidemiology in France (2019-2032)

Figure 8: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in France (2019-2032)

Figure 9: Familial Primary Pulmonary Hypertension Epidemiology in Italy (2019-2032)

Figure 10: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11: Familial Primary Pulmonary Hypertension Epidemiology in Spain (2019-2032)

Figure 12: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13: Familial Primary Pulmonary Hypertension Epidemiology in the UK (2019-2032)

Figure 14: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in the UK (2019-2032)

Figure 15: Familial Primary Pulmonary Hypertension Epidemiology in Japan (2019-2032)

Figure 16: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Japan (2019-2032)

Figure 17: Drug Name, Clinical Trials by Recruitment status

Figure 18: Drug Name, Clinical Trials by Zone

Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)

Figure 20: Region-wise Market Size in USD, Million (2019-2032)

Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Figure 22: United States Market Size in USD, Million (2019-2032)

Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)

Figure 24: Germany Market Size in USD, Million (2019-2032)

Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Figure 26: France Market Size in USD, Million (2019-2032)

Figure 27: France Market Size by Therapy in USD, Million (2019-2032)

Figure 28: Italy Market Size in USD, Million (2019-2032)

Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Figure 30: Spain Market Size in USD, Million (2019-2032)

Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Figure 32: United Kingdom Market Size in USD, Million (2019-2032)

Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Figure 34: Japan Market Size in USD, Million (2019-2032)

Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of figures is not exhaustive; the final content may vary

  • Liquidia Technologies
  • Acceleron Pharma
  • Altavant Sciences
  • United Therapeutics
  • Actelion

Forward to Friend

Need A Quote